UFP Technologies (UFPT) Q3 2026 earnings summary

Executive summary

• Q3 sales rose 11.6% to $172.4M, with 11.1% organic growth; gross margin reached 29.4%, and adjusted operating income grew 14.5%.

• Nine-month sales increased 10.3% to $500.6M, including 7.9% organic growth; net income rose to $59.0M from $50.7M.

• Strategy emphasizes organic investment, operational improvement, disciplined acquisitions and expanded capabilities for customer needs.

Financial highlights

• Q3 gross profit was $50.8M, operating income $27.6M and net income $20.6M; adjusted net income was $22.5M.

• Q3 GAAP diluted EPS was $2.64 and adjusted diluted EPS was $2.88, versus $2.11 and $2.39, respectively, a year earlier.

• Nine-month operating income reached $79.1M; adjusted net income rose 13.0% to $64.5M and adjusted diluted EPS was $8.28.

• Q3 SG&A increased 21.4% to $23.2M, driven by added headcount and back-office resources, higher share-based compensation and legal expenses.

Outlook and guidance

• Long-term framework remains 6%–9% organic growth and 12%–18% total growth including inorganic contributions; no quarterly or annual guidance was issued.

• Q4 is seasonally softer, with additional holiday shutdowns expected as more activity shifts to the Dominican Republic.

• DAS Medical capacity and program launches support expected double-digit growth in 2027; robotic surgical platforms may contribute meaningfully from 2027 onward.

• Gross margin outlook remains within 28%–31%, with management indicating a level near 29%.